氟氢可的松联合氢化可的松与单用氢化可的松在脓毒性休克患者中的比较效果
该研究为2016至2020年基于Premier Healthcare数据库的回顾性队列研究,采用目标试验模拟方法,纳入成人脓毒性休克且接受去甲肾上腺素并开始氢化可的松治疗的患者88 275例;暴露为开始氢化可的松同日加用氟氢可的松(2280例)vs 单用氢化可的松(85 995例)。主要复合结局为院内死亡或出院转临终关怀,氟氢可的松组发生1076例(47.2%),单用氢化可的松组发生43 669例(50.8%),校正绝对风险差-3.7%(95%CI -4.2%至-3.1%,P<.001)。作者结论认为,在开始氢化可的松治疗的成人脓毒性休克患者中,加用氟氢可的松优于单用氢化可的松。
要点
- 在成人脓毒性休克且接受去甲肾上腺素、开始氢化可的松治疗的患者中,同日加用氟氢可的松较单用氢化可的松降低院内死亡或出院转临终关怀复合结局(校正绝对风险差-3.7%,95%CI -4.2%至-3.1%,P<.001)。
- 氟氢可的松联合组复合结局发生1076/2280例(47.2%),单用氢化可的松组发生43 669/85 995例(50.8%)。
- 该研究为基于Premier Healthcare数据库(覆盖约25%美国住院)的回顾性队列研究,采用目标试验模拟与双稳健靶向最大似然估计计算校正风险差。
- 暴露定义为开始氢化可的松治疗当日加用氟氢可的松,与单用氢化可的松比较。
适用人群与场景
- 成人脓毒性休克住院患者,且正在接受去甲肾上腺素并开始氢化可的松治疗。
- 数据来源于2016至2020年Premier Healthcare数据库,覆盖约25%美国住院病例。
研究设计与关键结果
- 研究设计:2016至2020年回顾性队列研究,采用目标试验模拟方法,数据来自Premier Healthcare数据库,纳入88 275例成人脓毒性休克且接受去甲肾上腺素并开始氢化可的松治疗的患者。
- 暴露分组:氢化可的松联合氟氢可的松组2280例(中位年龄64岁,IQR 54-73;女性1041例,男性1239例);单用氢化可的松组85 995例(中位年龄67岁,IQR 57-76;女性42 136例,男性43 859例)。
- 主要复合结局(院内死亡或出院转临终关怀):联合组1076例(47.2%)vs 单用组43 669例(50.8%),校正绝对风险差-3.7%(95%CI -4.2%至-3.1%,P<.001)。
- 数据分析时间为2022年5月至2022年12月。
证据类型、等级与局限
- 证据类型:回顾性队列研究(目标试验模拟),采用双稳健靶向最大似然估计计算校正风险差。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在开始氢化可的松治疗的成人脓毒性休克患者中,加用氟氢可的松优于单用氢化可的松。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Patients with septic shock may benefit from the initiation of corticosteroids. However, the comparative effectiveness of the 2 most studied corticosteroid regimens (hydrocortisone with fludrocortisone vs hydrocortisone alone) is unclear.
OBJECTIVE: To compare the effectiveness of adding fludrocortisone to hydrocortisone vs hydrocortisone alone among patients with septic shock using target trial emulation.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study from 2016 to 2020 used the enhanced claims-based Premier Healthcare Database, which included approximately 25% of US hospitalizations. Participants were adult patients hospitalized with septic shock and receiving norepinephrine who began hydrocortisone treatment. Data analysis was performed from May 2022 to December 2022.
EXPOSURE: Addition of fludrocortisone on the same calendar day that hydrocortisone treatment was initiated vs use of hydrocortisone alone.
MAIN OUTCOME AND MEASURES: Composite of hospital death or discharge to hospice. Adjusted risk differences were calculated using doubly robust targeted maximum likelihood estimation.
RESULTS: Analyses included 88 275 patients, 2280 who began treatment with hydrocortisone-fludrocortisone (median [IQR] age, 64 [54-73] years; 1041 female; 1239 male) and 85 995 (median [IQR] age, 67 [57-76] years; 42 136 female; 43 859 male) who began treatment with hydrocortisone alone. The primary composite outcome of death in hospital or discharge to hospice occurred among 1076 (47.2%) patients treated with hydrocortisone-fludrocortisone vs 43 669 (50.8%) treated with hydrocortisone alone (adjusted absolute risk difference, -3.7%; 95% CI, -4.2% to -3.1%; P < .001).
CONCLUSIONS AND RELEVANCE: In this comparative effectiveness cohort study among adult patients with septic shock who began hydrocortisone treatment, the addition of fludrocortisone was superior to hydrocortisone alone.
参考来源
- Bosch NA, Teja B, Law AC, et al. Comparative Effectiveness of Fludrocortisone and Hydrocortisone vs Hydrocortisone Alone Among Patients With Septic Shock. JAMA Intern Med. 2023. PMID: 36972033. doi:10.1001/jamainternmed.2023.0258
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。